HMOX1 and COVID-19: There are numerous publications in recent years supporting the therapeutic utility of HO-1 induction against various pathogenic infections, first reported for HIV-1 in 2006 [6], and, now more recently, as a potentially viable therapeutic option for mitigating COVID-19 [16,17,18,19].